Back to Search Start Over

Dynavax Technologies commences dosing in Z-1018 phase 1/2 clinical trial

Source :
M2 Pharma. June 28, 2024
Publication Year :
2024

Abstract

M2 PHARMA-June 28, 2024-Dynavax Technologies commences dosing in Z-1018 phase 1/2 clinical trial (C)2024 M2 COMMUNICATIONS Dynavax Technologies Corporation (Nasdaq: DVAX), a California-based commercial-stage biopharmaceutical company, announced on Thursday that [...]

Subjects

Subjects :
Dynavax Technologies Corp. -- Product development
Biological products industry -- Product development
Medical research
Medicine, Experimental
Clinical trials
Vaccines -- Product development
Pharmaceutical industry -- Product development
Chemistry

Details

Language :
English
Database :
Gale General OneFile
Journal :
M2 Pharma
Publication Type :
News
Accession number :
edsgcl.799248041

Tools

Authors Abstract Subjects Details